PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 33237350-12 2020 We studied the expression of amino acid transporters (AATs) for 18F-Fluciclovine, namely LAT1 (SLC7A5 and SLC3A2) and ASCT2 (SLC1A5). fluciclovine F-18 64-80 solute carrier family 7 member 5 Homo sapiens 95-101 33237350-8 2020 Western blot, quantitative RT-PCR and next-generation sequencing transcriptomic analyses were performed to assess the expression levels of amino acid transporters (including LAT1 and ASCT2, which have been implicated for Fluciclovine uptake). fluciclovine F-18 221-233 solute carrier family 7 member 5 Homo sapiens 174-178 33237350-8 2020 Western blot, quantitative RT-PCR and next-generation sequencing transcriptomic analyses were performed to assess the expression levels of amino acid transporters (including LAT1 and ASCT2, which have been implicated for Fluciclovine uptake). fluciclovine F-18 221-233 solute carrier family 1 member 5 Homo sapiens 183-188 32796479-1 2020 PURPOSE: The aim of the study was to assess the diagnostic performance of fluciclovine positron emission tomography (PET)/computerized tomography (CT) in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen (PSA) <=0.5 ng/mL, and identify the associated predictive factors of positive studies. fluciclovine F-18 74-86 kallikrein related peptidase 3 Homo sapiens 218-243 33237350-14 2020 Additional AATs such as SLC43A2 (LAT4) were shown to be upregulated following chronic ADT by transcriptomic analysis; their role in Fluciclovine uptake warrants investigation. fluciclovine F-18 132-144 solute carrier family 43 member 2 Homo sapiens 24-31 33237350-14 2020 Additional AATs such as SLC43A2 (LAT4) were shown to be upregulated following chronic ADT by transcriptomic analysis; their role in Fluciclovine uptake warrants investigation. fluciclovine F-18 132-144 solute carrier family 43 member 2 Homo sapiens 33-37 34933313-0 2021 PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer. fluciclovine F-18 39-55 aminopeptidase puromycin sensitive Homo sapiens 0-3 34091713-1 2021 PURPOSE: 18F-Fluciclovine PET imaging has been increasingly used in the restaging of prostate cancer patients with biochemical recurrence (BCR); however, its clinical utility in patients with low prostate-specific antigen (PSA) levels following primary radiation therapy has not been well-studied. fluciclovine F-18 9-25 kallikrein related peptidase 3 Homo sapiens 196-221 34091713-2 2021 This study aims to determine the detection rate and diagnostic accuracy of 18F-fluciclovine PET and the patterns of prostate cancer recurrence in patients with rising PSA after initial radiation therapy, particularly in patients with PSA levels below the accepted Phoenix definition of BCR (PSA nadir +2 ng/mL). fluciclovine F-18 75-91 kallikrein related peptidase 3 Homo sapiens 167-170 34091713-3 2021 METHODS: This retrospective study included patients from two tertiary institutions who underwent 18F-fluciclovine PET scans for elevated PSA level following initial external beam radiation therapy, brachytherapy, and/or proton therapy. fluciclovine F-18 97-113 kallikrein related peptidase 3 Homo sapiens 137-140 34091713-4 2021 Logistic regression and receiver operating characteristic (ROC) curve analyses were performed to determine the diagnostic accuracy of 18F-fluciclovine PET and associations of PSA kinetic parameters with 18F-fluciclovine PET outcome. fluciclovine F-18 203-219 kallikrein related peptidase 3 Homo sapiens 175-178 34091713-9 2021 In patients with PSA below the Phoenix criteria, the PSA velocity had the highest predictive value of 18F-fluciclovine PET outcome. fluciclovine F-18 102-118 kallikrein related peptidase 3 Homo sapiens 53-56 34091713-11 2021 CONCLUSION: 18F-Fluciclovine PET can identify recurrent disease at low PSA level and PSA rise below accepted Phoenix criteria in patients with suspected BCR after primary radiation therapy, particularly in patients with low PSADT or high PSA velocity. fluciclovine F-18 12-28 kallikrein related peptidase 3 Homo sapiens 71-74 34091713-11 2021 CONCLUSION: 18F-Fluciclovine PET can identify recurrent disease at low PSA level and PSA rise below accepted Phoenix criteria in patients with suspected BCR after primary radiation therapy, particularly in patients with low PSADT or high PSA velocity. fluciclovine F-18 12-28 kallikrein related peptidase 3 Homo sapiens 238-241 34933313-0 2021 PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer. fluciclovine F-18 39-55 aminopeptidase puromycin sensitive Homo sapiens 8-11 34933313-3 2021 We explored the association between 18F-fluciclovine PET/CT positivity and prescan PSA, PSA doubling time, and PSA velocity in patients with biochemical recurrence (BCR) of PCa after curative-intent treatment. fluciclovine F-18 36-52 aminopeptidase puromycin sensitive Homo sapiens 83-86 34933313-3 2021 We explored the association between 18F-fluciclovine PET/CT positivity and prescan PSA, PSA doubling time, and PSA velocity in patients with biochemical recurrence (BCR) of PCa after curative-intent treatment. fluciclovine F-18 36-52 aminopeptidase puromycin sensitive Homo sapiens 111-114 34754611-9 2021 In conclusion, among prostate cancer patients with biochemical recurrence, 18F-fluciclovine PET/CT is useful in patients with very low serum PSA of <=0.3 ng/mL, with a 57.8% positivity rate, higher than previously reported. fluciclovine F-18 75-91 kallikrein related peptidase 3 Homo sapiens 141-144 32956127-3 2021 18F-fluciclovine uptake is mediated by amino acid transporters, primarily alanine-serine-cysteine transporter 2 and l-type amino acid transporter 1, previously demonstrated to be expressed on thymic carcinomas. fluciclovine F-18 4-16 solute carrier family 7 member 5 Homo sapiens 116-147 35174096-11 2022 Results: Within the multivariate regression, the fluciclovine TN uptake ratio (measured 15 to 35 minutes after fluciclovine injection) was most strongly associated with tumor ASCT2 levels (beta=0.64; P=0.001). fluciclovine F-18 49-61 solute carrier family 1 member 5 Homo sapiens 175-180 35174096-11 2022 Results: Within the multivariate regression, the fluciclovine TN uptake ratio (measured 15 to 35 minutes after fluciclovine injection) was most strongly associated with tumor ASCT2 levels (beta=0.64; P=0.001). fluciclovine F-18 111-123 solute carrier family 1 member 5 Homo sapiens 175-180 35174096-15 2022 Conclusions: Increased fluciclovine PET uptake was associated with increased levels of the amino acid transporter ASCT2, suggesting fluciclovine PET may be useful for assessing brain tumor amino acid metabolism. fluciclovine F-18 23-35 solute carrier family 1 member 5 Homo sapiens 114-119 35174096-15 2022 Conclusions: Increased fluciclovine PET uptake was associated with increased levels of the amino acid transporter ASCT2, suggesting fluciclovine PET may be useful for assessing brain tumor amino acid metabolism. fluciclovine F-18 132-144 solute carrier family 1 member 5 Homo sapiens 114-119 32504685-3 2021 RESULTS: The 3D MP MRI clarified the anatomy of the primary lesion and fluciclovine F-18 PET significantly improved our ability to stage the tumor prompting pelvic lymph node dissection that may have otherwise not been performed. fluciclovine F-18 71-83 mastermind like domain containing 1 Homo sapiens 84-88 34079638-0 2021 Diagnostic performance of 18F-fluciclovine PET/CT in prostate cancer patients with rising PSA level <= 0.5 ng/ml after multiple treatment failures. fluciclovine F-18 26-42 kallikrein related peptidase 3 Homo sapiens 90-93 34079638-1 2021 This retrospective study is to assess the performance of 18F-Fluciclovine PET/CT in prostate cancer (PC) patients with multiple treatment failures and prostate-specific antigen (PSA) <= 0.5 ng/mL. fluciclovine F-18 57-73 kallikrein related peptidase 3 Homo sapiens 151-176 34079638-1 2021 This retrospective study is to assess the performance of 18F-Fluciclovine PET/CT in prostate cancer (PC) patients with multiple treatment failures and prostate-specific antigen (PSA) <= 0.5 ng/mL. fluciclovine F-18 57-73 kallikrein related peptidase 3 Homo sapiens 178-181 33741863-0 2021 18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL. fluciclovine F-18 0-16 kallikrein related peptidase 3 Homo sapiens 92-95 33741863-7 2021 CONCLUSION: 18F-fluciclovine PET/CT demonstrated a detection rate of 56.4% among patients with a PSA below 2.0 ng/mL. fluciclovine F-18 12-28 kallikrein related peptidase 3 Homo sapiens 97-100 33741863-8 2021 The results of this study support the use of 18F-fluciclovine PET/CT for the detection of recurrent prostate cancer at lower PSA levels, even at PSA levels less than 0.5 ng/mL. fluciclovine F-18 45-61 kallikrein related peptidase 3 Homo sapiens 125-128 33469884-7 2021 RESULTS: The overall positivity rate of 18F-fluciclovine PET was 67 %, which, as expected, increased with higher prostate-specific antigen (PSA) levels (ng/ml): 15 % (PSA < 0.5), 50 % (0.5 <= PSA < 1), 56 % (1 <= PSA < 2), 68 % (2 <= PSA < 5), and 94 % (PSA >= 5), respectively. fluciclovine F-18 40-56 kallikrein related peptidase 3 Homo sapiens 113-144 33469884-7 2021 RESULTS: The overall positivity rate of 18F-fluciclovine PET was 67 %, which, as expected, increased with higher prostate-specific antigen (PSA) levels (ng/ml): 15 % (PSA < 0.5), 50 % (0.5 <= PSA < 1), 56 % (1 <= PSA < 2), 68 % (2 <= PSA < 5), and 94 % (PSA >= 5), respectively. fluciclovine F-18 40-56 kallikrein related peptidase 3 Homo sapiens 140-143 31182661-1 2019 18F-fluciclovine is a Food and Drug Administration-approved PET tracer indicated for patients suspected to have recurrent prostate cancer based on a prostate-specific antigen rise after prior therapy. fluciclovine F-18 0-16 kallikrein related peptidase 3 Homo sapiens 149-174 32569513-5 2020 Our results suggest that 18F-fluciclovine PET/CT can be helpful for localizing recurrence in patients with PSA levels between 0.3 and 1 ng/mL and that 18F-fluciclovine PET/CT is not recommended in patients with PSA levels less than 0.3 ng/mL. fluciclovine F-18 25-41 kallikrein related peptidase 3 Homo sapiens 107-110 32558719-0 2020 18F-Fluciclovine PET/MRI in a Patient With Squamous Cell Carcinoma of the Uterine Cervix Correlated With 18F-FDG PET/CT. fluciclovine F-18 0-16 single-strand-selective monofunctional uracil-DNA glycosylase 1 Homo sapiens 109-112 32604105-0 2020 Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment? fluciclovine F-18 22-38 kallikrein related peptidase 3 Homo sapiens 78-81 32879900-2 2020 However, because of inter- and intrareader variability in interpretation of F-18 fluciclovine positron emission tomography/computed tomography (PET/CT), it is difficult to reliably discern between necrotic tissue owing to radiation therapy and tumor tissue. fluciclovine F-18 81-93 mastermind like domain containing 1 Homo sapiens 76-80 32083008-7 2020 This is particularly the case of fluciclovine-PET and PSMA-PET in cases of biochemical recurrence with low values of prostate specific antigen. fluciclovine F-18 33-45 kallikrein related peptidase 3 Homo sapiens 117-142 33425735-17 2020 Conclusion: Combined 18F-fluciclovine PET/MRI can detect lesions suspicious for recurrent prostate cancer in patients with a range of PSA levels. fluciclovine F-18 21-37 kallikrein related peptidase 3 Homo sapiens 134-137 32396045-11 2020 Conclusion Patient-level detection rates for biochemically recurrent prostate cancer were greater for prostate-specific membrane antigen-targeted radiotracers than fluciclovine for prostate specific antigen levels of 1.0-1.9 ng/mL. fluciclovine F-18 164-176 kallikrein related peptidase 3 Homo sapiens 181-206 32317221-0 2020 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. fluciclovine F-18 0-16 kallikrein related peptidase 3 Homo sapiens 87-90 32317221-1 2020 OBJECTIVES: To evaluate various Prostate-Specific Antigen (PSA) thresholds at which a 18F-fluciclovine PET scan could be considered in the setting of biochemical recurrent prostate cancer after definitive treatment. fluciclovine F-18 86-102 kallikrein related peptidase 3 Homo sapiens 32-57 32317221-1 2020 OBJECTIVES: To evaluate various Prostate-Specific Antigen (PSA) thresholds at which a 18F-fluciclovine PET scan could be considered in the setting of biochemical recurrent prostate cancer after definitive treatment. fluciclovine F-18 86-102 kallikrein related peptidase 3 Homo sapiens 59-62 32068113-8 2020 RESULTS: 18F-Fluciclovine was well tolerated in the 104 scanned patients (median PSA = 0.79 ng/mL). fluciclovine F-18 9-25 kallikrein related peptidase 3 Homo sapiens 81-84 32068113-14 2020 Where 18F-fluciclovine guided salvage therapy, the PSA response rate was higher than when 18F-fluciclovine was not involved (15 out of 17 [88%] vs 28 out of 39 [72%]). fluciclovine F-18 6-22 kallikrein related peptidase 3 Homo sapiens 51-54 32149799-0 2020 Solitary Penile Metastasis of Prostate Cancer on 18F-Fluciclovine PET/CT Imaging in a Patient With PSA of 1 ng/mL. fluciclovine F-18 49-65 aminopeptidase puromycin sensitive Homo sapiens 99-102 32395349-1 2020 The positron emission tomography (PET) tracer 18F-fluciclovine has seen increasing use to localize disease in men with biochemical recurrence of prostate cancer, i.e., elevated prostate-specific antigen (PSA) levels post-treatment. fluciclovine F-18 46-62 kallikrein related peptidase 3 Homo sapiens 177-202 32395349-1 2020 The positron emission tomography (PET) tracer 18F-fluciclovine has seen increasing use to localize disease in men with biochemical recurrence of prostate cancer, i.e., elevated prostate-specific antigen (PSA) levels post-treatment. fluciclovine F-18 46-62 kallikrein related peptidase 3 Homo sapiens 204-207 32395349-5 2020 First, 18F-fluciclovine is a radiolabeled synthetic amino acid targeting the amino acid transporters ASCT2 and LAT1, which are ubiquitous throughout the body, but overexpressed in prostate cancer. fluciclovine F-18 7-23 solute carrier family 1 member 5 Homo sapiens 101-106 32395349-5 2020 First, 18F-fluciclovine is a radiolabeled synthetic amino acid targeting the amino acid transporters ASCT2 and LAT1, which are ubiquitous throughout the body, but overexpressed in prostate cancer. fluciclovine F-18 7-23 solute carrier family 7 member 5 Homo sapiens 111-115 32395349-8 2020 Third, 18F-fluciclovine PET/CT detection rates increase as PSA levels rise. fluciclovine F-18 7-23 kallikrein related peptidase 3 Homo sapiens 59-62 32399012-1 2020 18F-fluciclovine is a PET radiopharmaceutical used for the detection of recurrent prostate cancer in adult men after primary curative treatment with suspicion of recurrence based on elevated prostate-specific antigen level. fluciclovine F-18 0-16 kallikrein related peptidase 3 Homo sapiens 191-216 30077749-5 2018 Fluciclovine, also known as anti-1-amino-3-[18F]-fluorocyclobutane-1-carboxylic acid (Axumin), is a new PET radiotracer approved by the Food and Drug Administration in 2016 for the detection of suspected recurrent prostate cancer with elevated prostate-specific antigen levels. fluciclovine F-18 0-12 kallikrein related peptidase 3 Homo sapiens 244-269 31283597-2 2019 As an amino acid-based radiotracer transported by LAT-1 and ASCT-2 transporters, fluciclovine exploits the up-regulation of amino acid transporters in malignant cells. fluciclovine F-18 81-93 solute carrier family 7 member 5 Homo sapiens 50-55 31283597-2 2019 As an amino acid-based radiotracer transported by LAT-1 and ASCT-2 transporters, fluciclovine exploits the up-regulation of amino acid transporters in malignant cells. fluciclovine F-18 81-93 solute carrier family 1 member 5 Homo sapiens 60-66 31216198-15 2019 Commercially produced fluciclovine PET/CT has a high PR for detection of prostate cancer recurrence and is positively correlated with increasing PSA levels. fluciclovine F-18 22-34 kallikrein related peptidase 3 Homo sapiens 145-148 31470934-2 2019 Newer tracers such as F-18 Fluciclovine and C-11 Choline, are in theory subject to metabolic shifts and changes based on patients" insulin levels, and also require attention to achieving optimum patient preparation. fluciclovine F-18 27-39 insulin Homo sapiens 131-138 31152256-0 2019 Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. fluciclovine F-18 71-87 solute carrier family 1 member 5 Homo sapiens 114-151 31152256-0 2019 Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. fluciclovine F-18 71-87 solute carrier family 1 member 5 Homo sapiens 153-158 31152256-0 2019 Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. fluciclovine F-18 71-87 solute carrier family 7 member 5 Homo sapiens 164-195 31152256-0 2019 Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. fluciclovine F-18 71-87 solute carrier family 7 member 5 Homo sapiens 197-201 31152256-1 2019 PURPOSE: To evaluate the expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter1 (LAT1) in prostate cancer (PCa) and their impact on uptake of 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) which is approved for the detection of recurrent PCa. fluciclovine F-18 233-249 solute carrier family 1 member 5 Homo sapiens 39-76 31152256-1 2019 PURPOSE: To evaluate the expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter1 (LAT1) in prostate cancer (PCa) and their impact on uptake of 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) which is approved for the detection of recurrent PCa. fluciclovine F-18 233-249 solute carrier family 1 member 5 Homo sapiens 78-83 31152256-1 2019 PURPOSE: To evaluate the expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter1 (LAT1) in prostate cancer (PCa) and their impact on uptake of 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) which is approved for the detection of recurrent PCa. fluciclovine F-18 233-249 solute carrier family 7 member 5 Homo sapiens 121-125 31152256-12 2019 The uptake of 18F-fluciclovine correlated significantly with LAT1 expression (rho = 0.39, p = 0.01, for SUVmax at 2 min and rho = 0.39, p = 0.01 for VT). fluciclovine F-18 14-30 solute carrier family 7 member 5 Homo sapiens 61-65 31152256-14 2019 CONCLUSIONS: Our findings suggest that LAT1 is moderately associated with the transport of 18F-fluciclovine in local PCa not exposed to hormonal therapy. fluciclovine F-18 91-107 solute carrier family 7 member 5 Homo sapiens 39-43 30589673-0 2019 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA <= 1 ng/mL After Definitive Primary Treatment. fluciclovine F-18 0-16 kallikrein related peptidase 3 Homo sapiens 89-92 30077749-5 2018 Fluciclovine, also known as anti-1-amino-3-[18F]-fluorocyclobutane-1-carboxylic acid (Axumin), is a new PET radiotracer approved by the Food and Drug Administration in 2016 for the detection of suspected recurrent prostate cancer with elevated prostate-specific antigen levels. fluciclovine F-18 86-92 kallikrein related peptidase 3 Homo sapiens 244-269 29189374-1 2018 Prostate imaging with F-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC, F-fluciclovine) PET/CT scan (Axumin) was recently approved by the US Food and Drug Administration for men with suspected prostate cancer recurrence based on elevated blood prostate-specific antigen levels following prior treatment. fluciclovine F-18 32-77 kallikrein related peptidase 3 Homo sapiens 258-283 30031468-6 2018 This review provides a detailed overview of the use of F-18 fluciclovine PET in prostate cancer imaging. fluciclovine F-18 60-72 mastermind like domain containing 1 Homo sapiens 55-59 29189374-1 2018 Prostate imaging with F-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC, F-fluciclovine) PET/CT scan (Axumin) was recently approved by the US Food and Drug Administration for men with suspected prostate cancer recurrence based on elevated blood prostate-specific antigen levels following prior treatment. fluciclovine F-18 79-84 kallikrein related peptidase 3 Homo sapiens 258-283 29189374-1 2018 Prostate imaging with F-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC, F-fluciclovine) PET/CT scan (Axumin) was recently approved by the US Food and Drug Administration for men with suspected prostate cancer recurrence based on elevated blood prostate-specific antigen levels following prior treatment. fluciclovine F-18 115-121 kallikrein related peptidase 3 Homo sapiens 258-283 28267449-5 2017 This review provides a detailed overview of the use of F-18 fluciclovine PET in prostate cancer imaging. fluciclovine F-18 60-72 mastermind like domain containing 1 Homo sapiens 55-59 28641974-1 2017 We present the case of a 79-year-old man with an elevated postprostatectomy prostate-specific antigen level who was sequentially imaged with positron emission tomography/computed tomography (PET/CT) using 18F-fluciclovine followed by PSMA-targeted 18F-DCFPyL. fluciclovine F-18 205-221 folate hydrolase 1 Homo sapiens 234-238 27746282-13 2017 CONCLUSIONS: Fluciclovine (18F) is well tolerated and able to detect local and distant prostate cancer recurrence across a wide range of prostate specific antigen values. fluciclovine F-18 13-25 kallikrein related peptidase 3 Homo sapiens 137-162 24943499-6 2014 CONCLUSIONS: DHT enhanced the expression of ASCT2, the transporter responsible for anti-[(18)F]FACBC uptake, thereby increasing anti-[(14)C]FACBC uptake in AR-positive LNCaP cells. fluciclovine F-18 95-100 solute carrier family 1 member 5 Homo sapiens 44-49 27754421-9 2016 Fluciclovine inhibited P-gp, MRP4, OAT1, OCT2, and OATP1B1 (IC50 > 2.95 mM). fluciclovine F-18 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 23-27 27754421-9 2016 Fluciclovine inhibited P-gp, MRP4, OAT1, OCT2, and OATP1B1 (IC50 > 2.95 mM). fluciclovine F-18 0-12 ATP binding cassette subfamily C member 4 Homo sapiens 29-33 27754421-9 2016 Fluciclovine inhibited P-gp, MRP4, OAT1, OCT2, and OATP1B1 (IC50 > 2.95 mM). fluciclovine F-18 0-12 solute carrier family 22 member 6 Homo sapiens 35-39 27754421-9 2016 Fluciclovine inhibited P-gp, MRP4, OAT1, OCT2, and OATP1B1 (IC50 > 2.95 mM). fluciclovine F-18 0-12 solute carrier family 22 member 2 Homo sapiens 41-45 27754421-9 2016 Fluciclovine inhibited P-gp, MRP4, OAT1, OCT2, and OATP1B1 (IC50 > 2.95 mM). fluciclovine F-18 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 51-58 27056619-9 2016 The highest (18)F-fluciclovine activity seems to be present in triple-negative and NG3 subtypes. fluciclovine F-18 18-30 EGF like domain multiple 8 Homo sapiens 83-86 26278491-2 2015 Our previous study showed that ASCT2 (Na(+)-dependent amino acid transporter (AAT)) mediates fluciclovine uptake in androgen-dependent PCa cells; its expression is influenced by androgen, a key hormone in the progression of primary PCa and castration-resistant prostate cancer (CRPC). fluciclovine F-18 93-105 solute carrier family 1 member 5 Homo sapiens 31-36 26278491-8 2015 DHT enhanced ASCT2 expression in LNCaP, LN-Pre, and LN-REC4, but not in LNCaP-SF, and the responses of ASCT2 expression to DHT correlated with [(14)C]fluciclovine uptake. fluciclovine F-18 150-162 solute carrier family 1 member 5 Homo sapiens 103-108 26278491-9 2015 CONCLUSIONS: System ASC, especially ASCT2, could play a major role in [(14)C]fluciclovine uptake into CRPC-like and androgen-dependent PCa cells, suggesting [(18)F]fluciclovine-PET is applicable to the detection of CRPC as well as androgen-dependent PCa. fluciclovine F-18 77-89 solute carrier family 1 member 5 Homo sapiens 36-41 26278491-9 2015 CONCLUSIONS: System ASC, especially ASCT2, could play a major role in [(14)C]fluciclovine uptake into CRPC-like and androgen-dependent PCa cells, suggesting [(18)F]fluciclovine-PET is applicable to the detection of CRPC as well as androgen-dependent PCa. fluciclovine F-18 164-176 solute carrier family 1 member 5 Homo sapiens 36-41 27091135-5 2016 Positivity rates were higher with fluciclovine PET/CT than with CT at all prostate-specific antigen (PSA) levels, PSA doubling times and original Gleason scores. fluciclovine F-18 34-46 kallikrein related peptidase 3 Homo sapiens 74-105 27091135-5 2016 Positivity rates were higher with fluciclovine PET/CT than with CT at all prostate-specific antigen (PSA) levels, PSA doubling times and original Gleason scores. fluciclovine F-18 34-46 kallikrein related peptidase 3 Homo sapiens 101-104 26053708-11 2015 When the patients were divided into groups with different PSA levels, (18)F-fluciclovine had a superior detection rate for low, intermediate, and high PSA levels. fluciclovine F-18 76-88 kallikrein related peptidase 3 Homo sapiens 58-61 26053708-11 2015 When the patients were divided into groups with different PSA levels, (18)F-fluciclovine had a superior detection rate for low, intermediate, and high PSA levels. fluciclovine F-18 76-88 kallikrein related peptidase 3 Homo sapiens 151-154 23994214-6 2013 We found that anti-[14C]FACBC uptake in the presence of Na+ was strongly inhibited by L-glutamine and L-serine (the substrates for ASC system AATs), whereas L-phenylalanine and 2-amino-bicyclo[2,2,1]heptane-2-carboxylic acid (BCH, the substrates for L system AATs) robustly inhibited Na+-independent anti-[14C]FACBC uptake. fluciclovine F-18 24-29 PYD and CARD domain containing Homo sapiens 131-134 23994214-6 2013 We found that anti-[14C]FACBC uptake in the presence of Na+ was strongly inhibited by L-glutamine and L-serine (the substrates for ASC system AATs), whereas L-phenylalanine and 2-amino-bicyclo[2,2,1]heptane-2-carboxylic acid (BCH, the substrates for L system AATs) robustly inhibited Na+-independent anti-[14C]FACBC uptake. fluciclovine F-18 310-315 PYD and CARD domain containing Homo sapiens 131-134 24136390-4 2014 Over half of anti-[(14)C]FACBC uptake by T/B and tumor cells was mediated by Na(+)-dependent amino acid transporters (system ASC), whereas most [(14)C]Met transport in all cells was mediated by Na(+)-independent carriers (system L). fluciclovine F-18 25-30 PYD and CARD domain containing Rattus norvegicus 125-128 21958853-8 2012 In the presence of Na(+), glutamine and serine showed the strongest inhibitory effect against anti-[(14)C]FACBC uptake, suggesting that system ASC, especially ASCT2, is an important AAT for anti-[(14)C]FACBC. fluciclovine F-18 106-111 solute carrier family 1 member 5 Homo sapiens 159-164 21958853-8 2012 In the presence of Na(+), glutamine and serine showed the strongest inhibitory effect against anti-[(14)C]FACBC uptake, suggesting that system ASC, especially ASCT2, is an important AAT for anti-[(14)C]FACBC. fluciclovine F-18 106-111 solute carrier family 38 member 7 Homo sapiens 182-185